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Dual regulatory switch through interactions of
Tcf7l2/Tcf4 with stage-specific partners propels
oligodendroglial maturation
Chuntao Zhao1,2,*, Yaqi Deng1,2,*, Lei Liu1,3,*, Kun Yu1, Liguo Zhang2, Haibo Wang2, Xuelian He2,
Jincheng Wang2,4, Changqing Lu1, Laiman N. Wu2, Qinjie Weng4, Meng Mao3, Jianrong Li5, Johan H. van Es6,
Mei Xin2, Lee Parry7, Steven A. Goldman8, Hans Clevers6 & Q. Richard Lu2,3,9
Constitutive activation of Wnt/b-catenin inhibits oligodendrocyte myelination. Tcf7l2/Tcf4, a
b-catenin transcriptional partner, is required for oligodendrocyte differentiation. How Tcf7l2
modifies b-catenin signalling and controls myelination remains elusive. Here we define a
stage-specific Tcf7l2-regulated transcriptional circuitry in initiating and sustaining
oligodendrocyte differentiation. Multistage genome occupancy analyses reveal that Tcf7l2
serially cooperates with distinct co-regulators to control oligodendrocyte lineage progression.
At the differentiation onset, Tcf7l2 interacts with a transcriptional co-repressor Kaiso/Zbtb33
to block b-catenin signalling. During oligodendrocyte maturation, Tcf7l2 recruits and
cooperates with Sox10 to promote myelination. In that context, Tcf7l2 directly activates
cholesterol biosynthesis genes and cholesterol supplementation partially rescues
oligodendrocyte differentiation defects in Tcf712 mutants. Together, we identify stage-specific
co-regulators Kaiso and Sox10 that sequentially interact with Tcf7l2 to coordinate the switch
at the transitions of differentiation initiation and maturation during oligodendrocyte
development, and point to a previously unrecognized role of Tcf7l2 in control of cholesterol
biosynthesis for CNS myelinogenesis.
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O
ligodendrocyte (OL) myelination permits saltatory
propagation of nerve signals and is critical for cognitive
and motor functions in the vertebrate central nervous
system (CNS)1–5. During myelination, OLs pass through multiple
developmental stages, including OL precursor cell (OPC),
immature premyelinating OL and mature myelinating OL
stages. A series of signalling pathways including Wnt/b-catenin,
BMP/Id and Notch/Hes signalling have been shown to negatively
regulate OL differentiation6,7. Hyperactivation of canonical Wnt
signalling leads to the inhibition of OL differentiation and
myelination through constitutively activated b-catenin8–10,
Wnt3a ligand treatment11–13 or the loss of signalling inhibitors,
as observed in ApcMin (ref. 14) or Apc knockout mice15. In
addition to these signalling pathways that sense the presence of
extrinsic factors in the environment, intrinsic factors such as
transcription factors including Olig1/2, Sox10, Zeb2/Sip1, Yy1,
Zfp191 and Myrf/Gm98 positively regulate OL development6,7.
Despite the critical roles of these signalling pathways and
transcriptional regulators in OL differentiation, the means by
which different signalling pathways and transcriptional regulatory
circuitries are integrated to control OL differentiation remains
poorly understood.
Activation of Wnt signalling on Wnt ligand binding results in
the stabilization and subsequent nuclear translocation of
b-catenin16. Nuclear b-catenin binds to T-cell factor (TCF)/
lymphoid enhancer-binding factors including Tcf7l2 (a.k.a. Tcf4).
The TCF complex with nuclear b-catenin activates Wnt target
genes16 and b-catenin-mediated transcriptional activation is
principally through TCFs17. Tcf7l2 is a major transducer of
b-catenin activity17 and is highly expressed by OL lineage cells8,9.
Although hyperactive Wnt signalling inhibits OL differentiation,
intriguingly, the loss of the b-catenin effector Tcf7l2 leads to a
block of OL differentiation in Tcf7l2-null animals9,18. At present,
the mechanisms underlying Tcf7l2 regulation of CNS myelination
and remyelination remain elusive. Importantly, direct
transcriptional targets of Tcf7l2 have not been identified in
OLs, a particular concern, as Tcf7l2 is a known partner of
b-catenin, raising the paradox of how Tcf7l2 might exert
functions opposing inhibitory functions of b-catenin.
By generating mice lacking the Tcf7l2 DNA-binding
transcription-activating domain, we showed that Tcf7l2
transcriptional activity is crucial for OL myelination and
remyelination. We further conducted genome-wide chromatin
immunoprecipitation sequencing (ChIP-seq) profiling to
comprehensively map the Tcf7l2 direct targets at different
stages of OL development and find that Tcf7l2 engages the OL
genome through its sequential interactions with stage-specific
co-regulators, including the non-canonical Wnt signalling
repressor Kaiso/Zbtb33 at the early phase of OPC differentiation
and a differentiation-promoting factor, Sox10, later in OL
differentiation. Our data further suggest that Tcf7l2 interacts
with Kaiso to antagonize Wnt signalling activity at the
differentiation onset, while coordinating with Sox10 to promote
myelin gene expression during OL maturation. Furthermore,
we find that Tcf7l2 and Sox10 interaction controls the cholesterol
biosynthesis pathway for myelinogenesis. Thus, our studies
define stage-dependent functions of Tcf7l2 during OL lineage
development mediated through switching binding partners
and provide a molecular framework for understanding the
context-specific control of CNS myelination.
Results
Tcf7l2 transcriptional activity is vital for OL myelination.
Tcf7l2 consists of several functional domains including the
b-catenin-binding domain, Groucho/TLE-binding domain and
HMG (high mobility group) DNA-binding domain (Fig. 1a)19.
To assess the role of Tcf7l2 transcriptional activity during
OL development, we generated mutant mice carrying a
transcriptionally inactive Tcf7l2, in which the floxed Tcf7l2
exon 11 encoding the DNA-binding HMG box20,21 was
excised by an OL lineage-expressing Olig1-Cre9,22, to generate
a Tcf7l2 in-frame mutant without the HMG domain.
This yielded control (Tcf7l2fl/þ :Olig1-Creþ / ) and mutant
(Tcf7l2fl/fl: Olig1-Creþ / ) mice (designated as Tcf7l2DHMG;
Fig. 1a). We confirmed the excision of the exon 11 in
complementary DNAs of OPCs isolated from Tcf7l2DHMG
neonates by quantitative reverse transcriptase–PCR (qRT–PCR),
using primers spanning the deleted exon 11 (Fig. 1b). Expression
of Tcf7l2DHMG, but not full-length Tcf7l2 protein, was detected
in Tcf7l2-mutant spinal cords, although its level is lower when
compared with that of control animals by western blot analysis
(Fig. 1b).
To investigate OL differentiation in Tcf7l2 mutants, we first
examined myelin gene expression in the brain. In the
Tcf7l2DHMG cortex, we found that in contrast to their robust
expression in the control, Mbp and Plp1 (proteolipid protein 1)
expression was remarkably reduced at postnatal stages (Fig. 1c).
The dysmyelinating phenotype persisted to adulthood (Fig. 1c).
Myelin basic protein (MBP) expression or green fluorescent
protein (GFP) signals from the CNP-mGFP transgenic line23 was
also reduced at P14 (Fig. 1d,e), consistent with the sustained
decrease in the number of Plp1þ OLs at P60 (Fig. 1f).
Impaired terminal OL differentiation in Tcf7l2 mutants might
be due to a shortage in OPCs. We then assessed the formation of
cortical OPCs using platelet-derived growth factor receptor-a
(PDGFRa) immunolabelling and a PDGFRa-GFP reporter24.
In the Tcf7l2DHMG cortex at P7, the number of PDGFRaþ
OPCs was comparable to that in the control (Fig. 1g-j). The
rate of OPC proliferation was also unaltered, as shown by
5-bromodeoxyuridine (BrdU) incorporation (Fig. 1i,j).
Furthermore, inactivation of Tcf7l2 in the OL lineage did not
affect the generation of neurons, astrocytes or microglia, as
immunolabelled by NeuN, glial fibrillary acidic protein and Iba1,
respectively (Supplementary Fig. 1). These results indicated that
Tcf7l2 is not essential for OPC formation.
In light of OL differentiation deficits noted in the Tcf7l2
mutants, we used electron microscopy to analyse myelin sheath
morphologies in the corpus callosum and in optic nerves.
Consistent with the decrease in myelin gene expression in the
brain, the optic nerves of mutant mice exhibited a significantly
reduced proportion of myelinated axons at early postnatal stages
such as P14, this relative hypomyelination persisted into adulthood
(Fig. 1k). Similarly, hypomyelination was also observed in the
corpus callosum at P60 (Fig. 1l), in which the percentage of
myelinated axons remained significantly lower than controls
(Fig. 1m). These data suggest that the loss of Tcf7l2 transcriptional
activity impairs myelination in both developing and adult brains.
To further verify the stage-specific function of Tcf7l2 in OL
differentiation, we inactivated Tcf7l2 using other OL-lineage
expressing Cre drivers, including Olig2-Cre, the expression
of which begins in early OL progenitors8. Similar to Olig1-
Cre-mediated mutagenesis, ablation of Tcf7l2 by Olig2-Cre
resulted in a substantial reduction in the expression of the
myelin genes Mbp and Plp1 in the mutant cortex at P14
(Supplementary Fig. 2a). In addition, in mice with Tcf7l2 ablated
by a CNP-Cre line25, wherein Cre expression commences at early
postmitotic OPC stages, there was a significant decrease in the
number of CC1þ or MAGþ myelinating OLs (Supplementary
Fig. 2b,c). Together, these observations suggest that Tcf7l2
regulates myelination-associated gene expression and is critical
for OPC differentiation.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10883
2 NATURE COMMUNICATIONS | 7:10883 |DOI: 10.1038/ncomms10883 | www.nature.com/naturecommunications
Tcf7l2 activity is required for OL remyelination. In the devel-
oping spinal cord of Tcf7l2DHMG mice, expression of Mbp was
substantially reduced at P0 and P7 (Fig. 2a), whereas the number
of PDGFRaþ OPCs was comparable to controls at P7 and P14
(Supplementary Fig. 3). In adulthood at P60, however, Mbp
expression was similar to control (Fig. 2b). Consistently, myelin
ultrastructure, the percentage of myelinated axons and their
g-ratios were all comparable between control and adult
Tcf7l2DHMG spinal cord at P60 (Fig. 2c–e), indicating a delayed
myelination process in the Tcf7l2-mutant spinal cord.
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Figure 1 | OL differentiation defects in the brain of Tcf7l2DHMG mice lacking the DNA-binding HMG domain. (a) Schematic diagram shows domains in
Tcf7l2 (upper) and Cre-mediated excision (lower) of the floxed exon 11, which encodes the DNA-binding HMG domain. NLS: Nuclear localization sequence.
(b) Upper panel, expression of Tcf7l2 exon 11 in the mRNAs of OPCs isolated from control (Ctrl) and Tcf7l2DHMG brains at P2 was assayed by qRT–PCR
(n¼ 3 animals per genotype). Lower panel: western blot analysis of the spinal cords from control and Tcf7l2DHMG mice at P10 with anti-Tcf7l2 (amino-
terminal epitope) and glyceraldehydes 3-phosphate dehydrogenase (GAPDH; loading control). (c) Expression of Mbp and Plp1 in cortices from control and
Tcf7l2DHMG mice by in situ hybridization. Arrows indicate the cerebral white matter in coronal sections, except P60 Mbp in sagittal sections. (d) MBP
immunostaining in the cortices from control and Tcf7l2DHMG mice at P14 assayed by immunohistochemistry. (e) Expression of membrane-anchored
enhanced GFP (EGFP) driven by a CNP promoter in the cortices from control and Tcf7l2DHMG mice carrying the CNP-mGFP transgene at P14. (f)
Quantification of Plp1þ OLs (per mm2) in the cortex of control and Tcf7l2DHMG at P60; n¼ 3 animals per genotype. (g) The cortices of Ctrl and
Tcf7l2DHMG mice at P14 were immunostained with anti-PDGFRa antibody. (h) PDGFRaþ OPC numbers were quantified per mm2; n¼ 3 animals per
genotype. (i) BrdU incorporation in the cortex of control and Tcf7l2DHMG mice carrying PDGFRa-GFP reporter and pulse labelled with BrdU for 2 h at P14.
(j) BrdUþ/PDGFRaþ OPC cell numbers were quantified per mm2; n¼ 3 animals per genotype. (k,l) Electron microscopy of the optic nerves (OP) and
corpus callosum (CC) of control and Tcf7l2DHMG mice at P14 and P60. (m) The percentages of myelinated axons in the OP and CC at P14 and P60; n¼ 3
animals per genotype. Data are presented as mean±s.e.m. ***Po0.001; Student’s t-test. Scale bars, 100 mm (c,d), 50mm (e,g–j) and 2 mm (k,l).
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As myelination in the spinal cord fully caught up when the
Tcf7l2 mutants reached adulthood, we then capitalized on this
phenotype to assess the function of Tcf7l2 in remyelination by
employing the lysolecithin (LPC)-induced demyelination26. Local
injection of LPC in the white matter induces rapid myelin
breakdown and removal of myelin from adult CNS; myelin
regenerates through an OPC recruitment phase at 7 days post
lesion (dpl) and a remyelinating phase at 14 dpl26. In adult
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Figure 2 | Tcf7l2 ablation impairs remyelination in LPC-induced demyelinating animal model. (a,b) Expression of Mbp in the spinal cord from control
(Ctrl) and Tcf7l2DHMG mice at indicated neonatal and adult ages by in situ hybridization. (c) Electron microscopy of the spinal white matter of control and
Tcf7l2DHMG mice at P60. The percentages of myelinated axons (d) and g-ratio (e) in the spinal white matter of control and Tcf7l2DHMG mice at P60. The
data represent the means±s.e.m.; n¼ 3 animals per genotype. (f) Left: the location of LPC-induced lesion (DAPI counterstaining, dashed lines) in the spinal
cord. Right: in situ hybridization analysis showed re-expression of Tcf7l2 in the LPC-induced demyelinating lesions (demarcated with dashed lines) and
uninjured regions at 7 and 14 dpl in spinal cords of P60 mice. (g) In situ hybridization analysis of PDGFRa,Mbp and Plp1 in the lesion regions (demarcated with
dashed lines) at 14 dpl in spinal cords of P60 Ctrl and Tcf7l2DHMG mutant mice. Quantification of the numbers of PDGFRaþ OPC (h) and Plp1þ OL (i) at 14
dpl in spinal cords of P60 control and Tcf7l2DHMG mutant mice; n¼ 5 animals for each genotype. (j) Representative electron micrographs of spinal cords of
8-week-old control and Tcf7l2DHMG mice at 14 dpl. Arrow indicates the newly formed thin myelin sheath. (k) Quantification of the percentage newly
myelinated axons in spinal lesions of 8-week-old control and Tcf7l2DHMG mice at 14 dpl; n¼ 3 animals for each genotype. (l) Quantification of g-ratio of
newly myelinated axons in spinal lesions of 8-week-old control and Tcf7l2DHMG mice at 14 dpl; n¼ 3 animals for each genotype. Po0.001, Student’s t-test.
Data are presented as mean±s.e.m. **Po0.01, ***Po0.001; Student’s t-test. Scale bars, 100mm (a,b), 2mm (c,j) and 50mm (f,g).
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control mice, Tcf7l2 was drastically upregulated at 7 and 14 dpl
within the LPC lesions (Fig. 2f), consistent with the previous
findings8. To determine whether Tcf7l2DHMG is required for
myelin repair, we analysed myelin gene expression in the lesions
at 14 dpl, a phase of OL regeneration and remyelination.
Compared with controls, we detected substantially lower levels of
Mbp and Plp1 during remyelination in Tcf7l2DHMG mice
(Fig. 2g,i), although PDGFRaþ OPCs were generated normally
(Fig. 2g,h). Importantly, many fewer myelinated axons were
detected in the lesions of Tcf7l2DHMG mice than in controls
(Fig. 2j). The percentage and thickness of newly generated myelin
sheaths around axons were significantly reduced in the Tcf7l2
mutants (Fig. 2k,l). These observations indicate that Tcf7l2
activity is critical for remyelination after demyelinating injury.
Downregulation of myelin genes in Tcf7l2DHMG mutants. In
light of our data demonstrating impaired re/myelination
capacity in the absence of Tcf7l2, we sought to identify
the Tcf7l2-regulated genes. We carried out RNA-sequencing
(RNA-seq) analysis using the OL-enriched optic nerves from
control and Tcf7l2DHMG mice at P12, to identify differentially
expressed genes. In accordance with dysmyelinating phenotypes,
expression of myelin genes such as Cnp, Mbp, Ugt8a and Mog,
and myelination-regulatory genes such as Sox10, Olig1 and Myrf,
was significantly reduced in Tcf7l2 mutants (Fig. 3a,b). In
contrast, we observed an upregulation of OL differentiation
inhibitors, including Id2, Notch2, Tgfb1/Tgfbr3 and Bmp6, as well
as Wnt signalling pathway components including Wnt4/6, Axin2,
Ctnnb1, Ccnd1 and Sp5 (Fig. 3a,b). Gene ontology analysis of
downregulated genes identified cholesterol biosynthesis, axon
ensheathment, OL differentiation and myelination (Fig. 3c),
congruent with impaired OL differentiation in Tcf7l2 mutants.
We further confirmed the downregulation of these myelination-
associated genes and differentiation regulators by qRT–PCR
analysis (Fig. 3d). Moreover, overexpression of Tcf7l2 in OPCs
enhanced expression of myelin genes such as Mbp, Cnp, Plp1 and
Mag, while repressing Id2 expression (Fig. 3e). These observations
suggest that Tcf7l2 transcriptional activity is both necessary and
sufficient for OPC maturation.
Stage-specific Tcf7l2 targeting for OL lineage progression. To
determine the expression pattern of Tcf7l2 during OL lineage
progression, we treated rat OPCs with triiodothyronine (T3) for
different durations. Tcf7l2 messenger RNA upregulated in
differentiating OPCs after 1 and 3 days of T3-induced
differentiation (Fig. 3f), but fell to a lower level in terminally
differentiated OLs 5 days after T3 treatment. Similarly, Tcf7l2
immunoreactivity was weakly detected in PDGFRaþ OPCs but
increased substantially in CNPþ differentiating OLs and then
decreased in terminally differentiated MBPþ OLs (Fig. 3g).
To gain insights into the direct targets regulated by Tcf7l2, we
carried out ChIP-seq analysis for Tcf7l2-chromatin occupancy in
OPCs, immature OLs (iOL, OPC exposure to T3 for 1 day) and
maturing OLs (mOLs, OPC exposure to T3 for 3 days)27
(Fig. 3h). The closest annotated gene to each Tcf7l2-binding
site was identified as a presumed target. The number of
Tcf7l2-targeted sites was B1,125 in iOLs and 14,541 in mOLs,
respectively (Fig. 3i). The majority of Tcf7l2-binding peaks in
iOLs overlapped with those identified in mOLs, but were of
lower intensity (Fig. 3h). The increase in targeted sites and signal
intensity from OPC to mOL correlated with the progression of
OPC differentiation. In contrast, Tcf7l2-targeted sites in iOL and
mOLs, respectively, overlapped by only 10 and 3% with those in
other cell types such as H4IIE liver cells (Fig. 3i), suggesting that
Tcf7l2 targets unique sets of genes in the OL lineage and
possesses a distinct role in the control of OL differentiation.
The Tcf7l2-binding sites were co-localized with evolutionarily
conserved enhancer elements marked by an activating histone
mark H3K27ac28 in iOL and mOL cells (Fig. 3j,k). To evaluate the
global distribution of Tcf7l2-binding loci, we plotted the number of
Tcf7l2 sites against their distance to the nearest transcription start
site (TSS). We detected a strong enrichment for Tcf7l2 binding
around TSSs within 5-kb promoter regions of genes marked by the
histone mark H3k4me3 (ref. 29), in particular in mOLs (Fig. 3l).
These observations indicate that Tcf7l2 targets primarily to
enhancer/promoter regions to regulate target gene expression.
Wnt inhibitor Kaiso is a Tcf7l2 co-factor in iOLs. To investigate
whether certain DNA motifs were enriched in Tcf7l2-binding
sites, we applied a motif-discovery algorithm, HOMER30. The
sequence motif A(C/G)(A/T)TCAAAG identified in iOLs
matches the consensus-binding motif for Tcf7l2 in previous
ChIP-seq data sets (Fig. 4a)31,32. Enhancer regions typically
have binding sites for co-factors, which bind within B100 bp
of the Tcf7l2 peak summit. We found that a substantial
proportion (B28%) of Tcf7l2-binding sites were significantly
overrepresented with the binding-motif of Zbtb33/Kaiso (Fig. 4a).
Kaiso is a transcriptional repressor of Wnt signalling, it interacts
with TCF factors to inhibit b-catenin-dependent activation of
transcription33–35. Kaiso expression increased as OPC
differentiated into iOL, but downregulated in mOL by
qRT–PCR and western blot analyses (Fig. 4b,c). Consistently,
by immunostaining, in contrast to weak expression in PDGFRaþ
OPCs, Kaiso was upregulated and co-localized with Tcf7l2 in
iOLs (Fig. 4d), while downregulated in MBPþ OLs, suggesting a
potential role of Kaiso at the onset of OPC differentiation.
Gene ontology analysis indicated that Tcf7l2-targeted genes in
iOL were significantly enriched in components of the Wnt
signalling pathway (Fig. 4e). Tcf7l2 targeted to a number of the
prototypical Wnt-responsive genes including Axin2, Sp5, Lef1,
Ctnnb1 and Ccnd1 on the transition of OPCs to iOLs (Fig. 4f) and
this was maintained in mOLs. We further confirmed that these
loci were also co-occupied by Kaiso using ChIP–qPCR in iOLs
(Fig. 4g). To examine the effects of Kaiso on Wnt signalling
activity, we transfected Kaiso-expressing vectors together with
constitutively active b-catenin (DN89 b-catenin)36 and a
luciferase reporter for b-catenin/TCF activation, Topflash37,
into HEK293T cells. Expression of DN89 b-catenin activated
the Topflash reporter significantly; however, Kaiso expression
suppressed the Topflash activity induced by the activated b-
catenin (Fig. 4h). This suggests that Kaiso expression attenuates
Wnt signalling activation, which negatively regulates OL
differentiation8,9.
Co-immunoprecipitation revealed that endogenous Tcf7l2 and
Kaiso were co-associated in the same complex in iOLs (Fig. 4i).
To further investigate the functional interactions between Tcf7l2
and b-catenin or Kaiso, we performed co-immunoprecipitation in
293T cells transfected with expression constructs carrying Tcf7l2,
b-catenin or Kaiso alone or in combination. Consistent with
previous studies17, Tcf7l2 and b-catenin were detected in the
same complex; however, in the presence of Kaiso, the interaction
between Tcf7l2 and b-catenin was abolished (Fig. 4j). Similarly,
overexpression of Kaiso substantially attenuated the interaction
between endogenous Tcf7l2 and b-catenin in Oli-neu cells, an
oligodendroglial cell line38 (Supplementary Fig. 4a). These
observations suggest that Kaiso competes with b-catenin for
Tcf7l2 binding and thereby inhibits Wnt/b-catenin signalling.
Furthermore, overexpression of Kaiso in rat OPCs enhanced the
expression of myelin-associated genes such as Cnp, Mbp and Plp1
(Fig. 4k).
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To determine the effect of Kaiso on the genome occupancy of
Tcf7l2 on different target genes, we performed Tcf7l2 ChIP–
qPCR in primary rat OPCs transfected with a Kaiso-expressing
vector. We found that Tcf7l2 occupancy on the promoter of Wnt
target genes (that is, Sp5, Ctnnb1, Ccnd1, Wnt11 and Wnt10a)
was reduced in Kaiso-overexpressing cells (Fig. 4l). In contrast,
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blue colour. (b) Heatmap of representative altered gene expression in RNA-seq analysis of control and Tcf7l2DHMG optic nerves at P12. (c) GO analysis
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analysis of expression of myelination-related genes in rat OPCs after transfection with control and the Tcf7l2-overexpressing (OE) vectors for 72 h; n¼ 3
independent experiments. (f) Real-time qRT–PCR analysis of Tcf7l2 and Mbp expression in OL lineage cells. OPCs were cultured under differentiation
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Tcf7l2 occupancy between iOLs or mOLs and H4IIE liver cells. ChIP-seq binding profiles of Tcf7l2 around H3K27Ac peak summits in iOLs (j) and mOLs
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**Po0.01 and ***Po0.001; Student’s t-test. Scale bar, 50mm (g).
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Tcf7l2 occupancy on the promoter of a myelination-promoting
factor Myrf was enhanced (Fig. 4l), suggesting that Kaiso
expression levels modulate the genome occupancy of Tcf7l2 in
OPCs. To further examine the effect of Kaiso knockdown on the
OL differentiation programme, small interfering RNA (siRNA)
targeting Kaiso was transfected into rat OPCs and cultured under
differentiation conditions for 72 h. Kaiso knockdown resulted in
the downregulation of myelination-associated genes that included
Mbp, Plp1, Cnp, Mag and Myrf, while upregulating the Wnt
signalling effectors Sp5, Wnt10a, Wnt4 and Wnt11 (Fig. 4m),
all as compared with scrambled siRNA-transfected OPCs.
Furthermore, we found that Kaiso overexpression enhanced
the expression levels of myelin-associated genes, while Tcf7l2
knockdown blocked the ability of Kaiso to promote their
expression (Fig. 4n,o), suggesting that the effect of Kaiso on
enhancing OL differentiation gene expression depends on Tcf7l2.
In addition, to determine the in vivo role of Kaiso in OL
development, we analysed the phenotype of Kaiso-null mice39
and found that the number of CC1þ differentiating OLs and
MBP signal intensity were substantially reduced in the corpus
callosum of Kaiso mutants at P7 (Fig. 4p,q) compared with
controls, despite normal PDGFRaþ OPC formation (Fig. 4q).
Collectively, these data suggest that Kaiso promotes OPC
differentiation programmes, while repressing Wnt signalling
activity and is required for normal OL differentiation.
Sox10 is a Tcf7l2 co-regulator for OL maturation. As in iOLs,
we found that Tcf7l2-binding peaks in mOLs match its consensus
DNA-binding motif (Fig. 5a); however, B38% of Tcf7l2-binding
sites present in mOLs were predominantly enriched with the
Sox-consensus binding motif C(T/A)TTG(T/A)(T/A), which
matches most significantly with an OL differentiation-promoting
factor Sox10 motif40,41 in the HOMER-motif discovery
programme (Fig. 5a), but to a lesser extent with the
Kaiso-binding motif. To determine whether Sox10 and Tcf7l2
co-target to the same regulatory elements in mOL, we then
performed genome-wide occupancy of Sox10 in mOL using
ChIP-seq. We found that B44% of Tcf7l2 peak sets overlapped
with those of Sox10 occupancy (Fig. 5b and Supplementary
Fig. 5). Sox10 motifs were enriched in Tcf7l2-binding sites in
mOLs (Fig. 5b,c), suggesting that Tcf7l2 and Sox10 co-target the
same elements in mOLs. To further determine whether
Tcf7l2 may co-associate with Sox10, we performed co-
immunoprecipitation assays and showed that Tcf7l2 and Sox10
were present in the same complex in mOLs (Fig. 5d), suggesting
that Sox10 is a co-factor of Tcf7l2 during OL maturation.
A large proportion of Tcf7l2/Sox10 co-occupancy was within
the regulatory elements of myelination-associated genes including
Mbp, Myrf, Olig1, Utg8 and Zfp191 in mOLs, but not in OPCs or
iOLs (Fig. 5e). In addition, although Sox10 or Tcf7l2 expression
in rat OPCs elevated the expression level of myelin-associated
genes such as Mbp and Cnp, co-expression of Sox10 and Tcf7l2
further increased their levels (Fig. 5f), suggesting that Sox10 and
Tcf7l2 cooperate to promote myelin gene expression.
How does Tcf7l2 coordinate distinct co-factors to control OL
lineage progression? Kaiso expression increases in iOL, but
downregulates in mOL, while the Sox10 expression level is
maintained throughout the OL lineage. To determine whether the
temporal sequence of Tcf7l2 recruitment of Kaiso and Sox10
depends on their expression levels, we co-transfected Tcf7l2 with
a varied amount of Kaiso, while keeping the Sox10 level constant
in 293T cells. We found that Tcf7l2 was associated preferentially
with Kaiso when Kaiso expression levels were high (Fig. 5g).
As the Kaiso level fell, Tcf7l2 was found to interact with Sox10
(Fig. 5g). Furthermore, we found that overexpression of Sox10
substantially reduced association of Tcf7l2 with Kaiso in Oli-neu
cells (Supplementary Fig. 4b), suggesting dosage-dependent
competitive binding of Tcf7l2 with Kaiso and Sox10. Thus,
there appears to be a two-step recruitment process in which
Tcf7l2 association with ‘early-‘ and ‘late-binding’ transcription
factors, Kaiso and Sox10, respectively, is responsible for OL
lineage progression. Together, these observations suggest that
Tcf7l2 coordinates the stepwise OL differentiation process
through interacting with Kaiso to suppress inhibitory Wnt
signalling in OPCs, while associating with Sox10 to promote
myelination-associated programmes during OL maturation
(Fig. 5h).
Tcf7l2 activates cholesterol biosynthesis for OL maturation.
Superimposing Tcf7l2 ChIP-seq from mOLs and RNA-seq data
revealed that B174 targeted genes with substantial changes of
expression in Tcf7l2DHMG mutants also exhibited strong Tcf7l2
binding to their proximal promoter regions (Fig. 6a). These genes
were overrepresented in the functional categories of steroid
biosynthesis and cholesterol metabolism (Fig. 6b). Among these
Tcf7l2 targets in mOLs, we identified a cohort of genes that
encode enzymes involved in de novo cholesterol biosynthesis,
including hmgcs1, Fdps, Fdft1, Lss, Cyp51, Hsd17b7 and
Dhcr24 (Fig. 6c,d). Although Tcf7l2 did not appear to
directly target the gene locus of Hmgcr (Supplementary Fig. 6a), it
was highly enriched on the promoter region of Srebf2
(Supplementary Fig. 6b), a key upstream regulator of Hmgcr
expression42,43.
When comparing Tcf7l2 occupancy on the promoters of
cholesterol pathway genes with that of Olig2, an OL specification
factor, we found that Tcf7l2 targeting was substantially enriched
in parallel with OL maturation, and that these promoters were
marked with the activating histone marks H3K4me3 and
H3K27Ac28,29 (Fig. 6d). In contrast, Olig2 binding on these
promoter regions was barely detectable in mOLs (Fig. 6d),
suggesting a distinct role between Olig2 and Tcf7l2 in the
differentiation of mOLs.
We next asked whether Tcf7l2 acted with partners to support
oligodendrocytic cholesterol synthesis and found that in mOLs,
Tcf7l2 co-occupied the promoters of cholesterol pathway genes
with Sox10 (Fig. 6d); ChIP–qPCR further confirmed the
enrichment of Tcf7l2 and Sox10 binding on the promoter
elements of these cholesterol synthetic genes (Fig. 6e). The
co-occupancy of the gene loci by Tcf7l2 and Sox10 is consistent
with observations that Tcf7l2 and Sox10 form a complex in mOL.
The presence of H3K4me3 and H3K27Ac in the targeted
promoters, both of which are indicators of active transcription
state28,29, suggests that Tcf7l2 positively regulates expression of
cholesterol biosynthesis genes (Fig. 6d). Accordingly, the mRNA
expression levels of these Tcf7l2-targeted cholesterol biosynthesis
genes was significantly reduced in Tcf7l2DHMG mutant optic
nerves (Fig. 6f).
To compare the activity of Tcf7l2 with a key regulator for the
cholesterol biosynthesis Srebf2/Srebp2 on target gene expression,
we cloned the promoter regions carrying Tcf7l2-binding sites of
cholesterol biosynthesis genes including Srebf2, Hmgcs1, Hmgcr,
Fdps, Lss, Cyp51, Hsd17b7 and Dhcr24 into a luciferase reporter
system. We found that similar to Srebf2, Tcf7l2 stimulated
the luciferase reporter activity driven by these regulatory
elements/enhancers (Fig. 6g). In contrast, these effects could
not be observed with Tcf7l2DHMG (Fig. 6g).
To further explore the relative contribution of Tcf7l2 to
expression of cholesterol biosynthesis genes in OLs, we next
transfected purified OPCs with control and expression vectors
carrying Tcf7l2 and found that overexpression of Tcf7l2 induced
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the expression of a number of genes encoding essential enzymes
for cholesterol synthesis, including Lss, Cyp51, Hsd17b7 and
Dhcr24 (Fig. 6h), as well as Axin2, a generic Wnt/Tcf7l2
target gene, and the myelination-promoting gene Myrf, suggest-
ing that activation of Tcf7l2 promotes expression of cholesterol
biosynthesis genes for OL differentiation.
Tcf7l2-induced cholesterol synthesis for OL differentiation.
Cholesterol biosynthesis is required for myelin sheath outgrowth
as shown in Hmgcs1 mutant zebrafish44 and Fdft1 mutant mice45.
To determine the role of other Tcf7l2-regulated cholesterol
biosynthesis genes in OL differentiation, we carried out siRNA
knockdown during OPC differentiation. Knockdown of Cyp51,
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Dhcr24, Hsd17b7 and Lss (Fig. 7a) reduced expression of myelin
genes including Mbp, Plp1, Cnp and Mag, although Id2 and Id4
expression was not significantly altered (Fig. 7b).
As Tcf7l2 activated the expression of cholesterol biosynthesis
genes, we hypothesized that dysregulation of cholesterol synthesis
might account for the impairment of OL maturation in
Tcf7l2DHMG mice. Previous studies reported that cholesterol, a
rate-limiting lipid component for myelin sheath growth, is not
imported into the brain from the circulation but rather
synthesized locally by myelin-forming OLs46,47. On that basis,
we next asked whether exogenous cholesterol would restore the
differentiation capacity of OPCs isolated from Tcf7l2 mutants.
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Under differentiation conditions, control OPCs readily
differentiated into CNPþ and MBPþ mature OLs, whereas the
majority of Tcf7l2-mutant OPCs failed to mature into OLs with
elaborate membrane processes (Fig. 7c). In addition, the
proportion of CNPþ or MBPþ OLs was significantly reduced
in Tcf7l2 mutants compared with controls (Fig. 7d,e). Strikingly,
exogenous cholesterol partially restored the percentage of CNPþ
and MBPþ OLs in mutant cultures (Fig. 7c–e). Consistently,
expression of myelin-associated genes increased in Tcf7l2-mutant
OPCs treated with cholesterol (Fig. 7f). To further determine
whether cholesterol supplementation could rescue the OL
differentiation defect in Tcf7l2-mutant animals, we fed the
pregnant mice carrying control and Tcf7l2DHMG mutants with
cholesterol-enriched diet during gestation, to allow cholesterol
intake into the CNS. The pups were harvested at P14 for analysis.
Although cholesterol supplementation did not alter the number
of OLs in the spinal cords of control animals, it significantly
increased the number of CC1þ OLs and expression of MBP in
Tcf7l2 mutants (Fig. 7g,h). These observations suggest that
cholesterol is responsible, at least in part, for Tcf7l2-dependent
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Figure 7 | Induction of cholesterol biosynthetic pathway by Tcf7l2 is required for OL differentiation. (a) Inhibition of cholesterol biosynthetic genes in
OPCs transfected with scrambled control siRNAs or siRNAs against Lss, Cyp51, Hsd17b7 and Dhcr24. (b) Downregulation of expression of myelin genes in
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in d–f and h. Scale bar, 50mm (c).
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control of OL differentiation, and that Tcf7l2 directly activates the
genes encoding cholesterol biosynthesis enzymes to promote OL
differentiation and maturation.
Discussion
Wnt/b-catenin/Tcf7l2 signalling has been suggested to positively
or negatively regulate OL development, which may depend on the
context8,9,48–51. Identification of Tcf7l2 direct targets and its
co-regulators is of vital importance to understand the Tcf7l2-
mediated process for OL development. Using integrative unbiased
genomics analyses of multiple stages in the OL lineage, we present
the first genome occupancy mapping of stage-specific targets of
Tcf7l2 during OL lineage progression and further identify
Tcf7l2-engaging partners that control transcriptional switches at
the transitions of differentiation initiation and OL maturation.
Strikingly, we uncover a non-canonical Wnt signalling co-
repressor Kaiso as a Tcf7l2 partner at the OL differentiation
onset to inhibit b-catenin activity. During OL maturation, Tcf7l2
further recruits another partner Sox10, a differentiation-
promoting factor, to activate the myelinogenic transcriptional
programme. Thus, Tcf712 executes a dual regulatory control by
recruiting stage-specific partners to switch its functions to propel
stepwise OL differentiation. Importantly, our studies further
provide evidence that Tcf7l2 directly targets and activates
cholesterol metabolism-associated genes and thereby regulates
de novo cholesterol biosynthesis necessary for myelinogenesis,
pointing to a previously unappreciated role of Tcf7l2 for
cholesterol homeostatic control of CNS myelination.
Constitutive activation of Wnt/b-catenin signalling inhibits OL
differentiation, suggesting that Wnt signalling may need to be
attenuated for developmental OL differentiation. We found that
the association of Kaiso with Tcf7l2 reverses the role of the
b-catenin/Tcf7l2-mediated transcriptional complex from a
differentiation repressor to an activator, which then promotes
the transition of OPCs from an undifferentiated to differentiating
state. At the onset of OPC differentiation, Kaiso is upregulated
and appears to act as a competitive inhibitor of b-catenin, to
oppose Wnt signalling activation by disrupting the b-catenin/
Tcf7l2 complex. Kaiso has been shown to interact with the NCoR/
Hdac1 complex to repress target gene expression35,52. It is
possible that Tcf7l2 forms a potent repressive complex with Kaiso
and Hdac1/2, and perhaps Hdac-associated Groucho/TLE
repressors as well9,53, so as to inhibit Wnt/b-catenin signalling.
Our data indicate that Tcf7l2 targets a number of prototypical
Wnt-responsive genes, including Axin2, Ccnd1, Ctnnb1, Lef1 and
Sp5 on OPC differentiation into iOLs and persists with
maturation (Fig. 4f). This suggests that Tcf7l2 may continue to
modulate b-catenin activation and downstream target expression
during OL differentiation. Persistent control of Wnt target gene
expression and signalling by Tcf7l2 and its co-factors probably
generates a high degree of regulatory complexity in response to
different Wnt signalling inputs over the course of OPC
differentiation.
We found that the transcriptional activity of Tcf7l2 is critical
for OL differentiation and myelin repair. Although we could not
rule out a potential dominant-negative effect of the Tcf7l2
mutant, the Tcf7l2DHMG mutant mice yielded a dysmyelinating
phenotype similar to that of full-length Tcf7l2-deletion mutants18.
Of note, we did not observe any discernable phenotype in
Tcf7l2DHMG heterozygous mice. It thus seems unlikely that any
dominant-negative effect would significantly contribute to the
dysmyelinating phenotype. Although Tcf7l2DHMG was able to
interact with Kaiso and Sox10 when overexpressed in 293T cells
(Supplementary Fig. 7a,b), it could not activate myelin gene
expression as wild-type Tcf7l2 (Supplementary Fig. 7c), but rather
blocks Kaiso and Sox10 activity for myelin gene activation
(Supplementary Fig. 7d,e). This suggests that Tcf7l2 activity is
required for OL differentiation-promoting machinery.
Tcf7l2DHMG mutant protein appears at a lower level in the
Tcf7l2-mutant spinal cord compared with its wild-type
counterpart (Fig. 1b). This is probably due to the severe
reduction of differentiating OLs, where Tcf7l2 is highly
expressed, in the mutants.
During OL maturation, we detect stronger signal intensity and
an increase in Tcf7l2-targeted binding sites, which largely overlap
with those identified in rat spinal cord54 (Supplementary Fig. 8).
We find that Sox10 acts a co-regulator with Tcf7l2 in mOLs, and
that Tcf7l2 and Sox10 cooperate to promote myelinogenic
programmes, consistent with the notion that Tcf7l2 has a
b-catenin independent function during OL differentiation18.
These findings suggest that Tcf7l2 functions through the
sequential operation of two interlaced gene regulatory networks:
one blocking inhibitory Wnt signalling activity at iOL stages
through recruiting transcriptional repressors such as Kaiso, and
the other promoting a ‘terminal’ differentiation process in
committed OLs in cooperation with Sox10. The switch of
Tcf7l2 co-regulators from Kaiso to Sox10 while transitioning
from iOL to mOLs may lead to the further induction of
myelin-specific genes, thus facilitating OL maturation (Fig. 5h).
Cooperation with stage-specific, transiently expressed
transcriptional partners may also explain the distinct stage-
specific role of Tcf7l2 in the initiation and maintenance of OL
differentiation.
Besides the temporally dynamic nature of Tcf7l2 interactions
with other transcriptional modulators, we have also observed a
distinct role for Tcf7l2 in regulating the extent of myelination. In
contrast to persistent myelination defects in the brain of Tcf7l2
mutants, Tcf7l2 appears dispensable for myelination in the adult
spinal cord, where Tcf7l2 is hardly detectable. At present, the
underlying mechanisms for this regional specificity remain
undetermined. The efficient Tcf7l2 allele recombination in the
spinal cord (Fig. 1b) indicates that a region-specific function of
Tcf7l2 rather than incomplete recombination accounts for the
phenotypic difference.
A novel finding of our present study is that Tcf7l2 directly
regulates de novo cholesterol biosynthesis and metabolism. We
find that Tcf7l2 target genes are selectively enriched on the
promoter regions of genes involved in cholesterol biosynthesis in
mOLs. In contrast, in liver cells, Tcf7l2 targets are enriched on the
promoter/enhancers of classical lipid synthesis-related genes such
as Fabp1, Apod, Scd1, Mttp, Hnf4a and Fas, which are associated
primarily with lipid metabolic pathways, such as the synthesis of
ketone bodies, transport of fatty acids and gluconeogenesis32,55
(Supplementary Fig. 9). This suggests a conserved yet distinct role
for Tcf7l2 in the control of lipid biosynthesis and metabolism, by
regulating different sets of genes in a cell-type-specific manner.
Cholesterol is a rate-limiting lipid component for OL
myelination and myelin sheath growth46,47. Defects in
myelination has been observed in mutants in the genes
responsible for cholesterol biosynthesis such as in Fdft1 mutant
mice45 and in Hmgcs1 mutant zebrafish44. We find that
cholesterol supplementation could, at least in part, rescue OL
differentiation defects in Tcf7l2DHMG mutants. Interestingly, a
similar observation was recently reported that cholesterol
injection could rescue the axon wrapping defect in hmgcs1
mutant zebrafish, suggesting that cholesterol synthesis is
necessary for OL maturation and axon wrapping44. A cell
sensing insufficient cholesterol could block OL differentiation and
expression of myelination-associated genes. It is possible that a
negative feedback or ‘check point’ mechanism exists, whereby
sufficient cholesterol biosynthesis for myelin biosynthesis must be
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verified before transcription of myelination-promoting factors.
Given that Tcf7l2 mutations lead to downregulation in the
expression of cholesterol biosynthesis enzymes, the requirement
of Tcf7l2 for OL myelination can be mediated, at least partially,
through its role as a regulator of cholesterol biosynthesis
during OL maturation. Collectively, Tcf7l2 may have a parallel
role in regulating the expression of cholesterol biosynthesis genes
in addition to directly activating the myelinogenic transcriptional
programme.
Previous studies show that TCF7L2 expression rose during
active remyelination in both human patients and rodent
models8,56, and yet is completely absent in the lesions of
chronic multiple sclerosis57. This observation suggested the
potential requirement of TCF7L2 for active myelin repair. Here
we provide evidence that Tcf7l2 transcriptional activity is crucial
for remyelination after demyelination, as well as to normal myelin
formation during brain development. Indeed, as the impact of the
Tcf7l2 knockout on myelination is more severe in the brain than
in the spinal cord, it would seem likely to be that the
remyelination defects observed in the Tcf7l2DHMG spinal cord
should manifest in the brain as well.
Recent studies indicate that TCF7L2 is a key regulator of the
metabolic gene programme that controls transcriptional
responses to metabolic challenge in the liver, muscle or white
adipose tissues32. For instance, TCF7L2 single-nucleotide
polymorphism variants and mutations contribute to type 2
diabetes mellitus58–60. Yet, type 2 diabetes impairs OL
regeneration in the white matter lesions after ischaemic
injury61. Our findings suggest then that TCF7L2 mutations or
single-nucleotide polymorphism variants might modify both the
degree of ischaemic myelin damage in patients with type 2
diabetes and their ability to remyelinate. Together, integrative
analyses of Tcf7l2 occupancy, gene expression profiling and
binding motifs at multiple OL stages reveal that Tcf7l2 appears to
exercise its functions by cooperating with stage-specific
co-regulators to control OL differentiation programmes.
More broadly, the present genome-wide Tcf7l2 target
identification should provide us a framework to identify novel
therapeutic avenues for myelin repair in the CNS.
Methods
Generation of Tcf7l2 conditional knockout mice. Tcf7l2 floxed mice20 were
crossed with Olig1-Cre22, Olig2-Cre62 (Olig2otm2(TVA,cre)Rth4/J from Jackson
Laboratory) and CNP-Cre25 (gift of Dr Klaus-Armin Nave) mice to generate
Tcf7l2DHMG (Tcf7l2fl/fl:CNP-Creþ / ) and heterozygous control (Tcf7l2 fl/þ :
CNP-Creþ / ) mice. As LoxP sites flank exon 11 encoding the highly conserved
DNA-binding domain of Tcf7l2, Cre-mediated recombination results in Tcf7l2
mutant protein lacking DNA-binding transcriptional activity, while the mutant
mRNA and protein may still be expressed. The control mice developed and
behaved the same as wild type. PDGFRa–GFP (Jackson Laboratory Stock Number
024098) and CNP-mGFP reporter mice23, and Zbtb33/Kaiso mutant mice39 were
used for phenotype analysis. We used both male and female mice for the study.
The mouse strains used in this study were generated and maintained on a mixed
C57Bl/6;129Sv;CD-1 background. All animal use and studies were approved by
ethical committees of our institutions and by the Institutional Animal Care and
Use Committee of Cincinnati Children’s Hospital Medical Center, USA.
Tissue processing and histochemistry. CNS tissues were dissected and fixed
overnight in 4% (w/v) paraformaldehyde (PFA) and processed for cryosectioning
or paraffin embedding and sectioning. The tissue processing and immunohisto-
chemical staining procedures were performed as described previously27. Briefly, for
tissue immunostaining, cryosections were incubated overnight in primary
antibodies diluted in block solution (PBS with 5% v/v normal goat serum
(Sigma-Aldrich, St Louis) and 0.3% v/v Triton X-100). After washing with PBS,
sections were then incubated overnight at 4 C with corresponding Cy2 or Cy3
fluorophore-conjugated secondary antibodies (Jackson ImmunoResearch). For
BrdU staining, cells or tissue sections were denatured with 0.1N HCl for 1 h in a
37 C water bath. After denaturation, sections were neutralized with 0.1M Borax
pH 8.5 (Sigma) for 10min. Sections were washed with 0.3% Triton X-100/1 PBS
(wash buffer) for three times and blocked with 5% normal donkey serum (Sigma-
Aldrich) containing wash buffer for 1 h at room temperature. Mouse anti-BrdU
(BD Bioscience, 550891, 1:500) antibody was used to label BrdU overnight at 4 C.
Samples were mounted in Fluoromount G (SouthernBiotech) for fluorescent
microscopy. For BrdU incorporation analysis, control and Tcf7l2DHMG
littermates were injected with BrdU (Sigma-Aldrich) (100mg kg 1 body weight)
2 hr before killing. Primary antibodies used were as follows: Olig2 (Millipore,
AB9610, 1:1,000), BrdU (BD Bioscience, 550891, 1:500), PDGFRa (BD Bioscience,
558774, 1:500), CC1 (Calbiochem, OP80, 1:500), NeuN (Millipore; MAB377,
1:500), GFAP (Sigma, G3893, 1:500), MBP (Santa Cruz; sc-13914, 1:500), Sox10
(Santa Cruz, sc-17343, 1:300); Tcf7l2 (Cell Signaling Technology, #2565, 1:500),
FLAG (Cell Signaling Technology, #2368, 1:500), Myc (Santa Cruz, sc-789, 1:500),
MAG (Cell Signaling Technology, #9043, 1:500), Iba1 (Waco; 019-19741, 1:400)
and Kaiso (Abcam, ab12723, 1:300). The Kaiso antibody was validated with vectors
expressing Kaiso and Myc-tag Kaiso-transfected 293T cells by western blotting and
immunostaining (Supplementary Fig. 10a,b). In addition, Kaiso expression was
abolished in the brain of Kaiso-null mice by western blot analysis (Supplementary
Fig. 10c), confirming the antibody specificity.
RNA in situ hybridization was performed using digoxigenin-labelled riboprobes
as described previously63. The probes used were as follows: murine PDGFRa,
Plp1/Dm-20 and Mbp.
Oligodendroglial cell culture and transfection. Isolation of primary rat OPCs
from cortices of P2 pups was performed as previously described64. OPCs were
differentiated in OL differentiation medium (Sato medium supplemented with
15 nM T3 and 10 ngml 1 ciliary neurotrophic factor) for 24 and 72 h to become
iOL and mOL as the initiation and maturing phases of OLs, respectively, as
previously described27. Mouse OPCs were isolated from P5 to P7 cortices of
control and Tcf7l2DHMG mutants by immunopanning with antibodies Ran-2,
GalC and PDGFRa sequentially as previously described65. The mouse OL cell line
Oli-neu cells were maintained in proliferation medium consisting of DME/F12
medium supplemented with Sato, NT3, CNTF, B27, 0.5 mM T3, 0.5 mM T4 and 1%
horse serum. The cells were induced to differentiate with 1mM cyclic AMP
supplementation38.
Primary rat OPCs or Oli-neu cells were transfected with control and
corresponding expression vectors carrying Tcf7l2, Tcf7l2DHMG and Kaiso, or
siRNAs by using Nucleofector (Lonza) according to the manufacturer’s protocol.
The cells were harvested 72 h after transfection and processed for qRT–PCR or
western blot analysis. siRNAs were purchased from Sigma-Aldrich with the
following catalogue numbers: for Cyp51 (SASI_Rn02_00342897), Dhcr24
(SASI_Rn02_00228595, SASI_Rn02_00228596, SASI_Rn02_00228597), Lss
(SASI_Rn01_00111479, SASI_Rn01_00111481, SASI_Rn01_00111484), Hsd17b7
(SASI_Rn02_00242485, SASI_Rn02_00242486, SASI_Rn02_00242487), Kaiso
(SASI_Rn02_00247204, SASI_Rn02_00247205, SASI_Rn02_00247206) and Tcf7l2
(SASI_Mm01_00142189, SASI_Mm02_00315891, SASI_Mm01_00142191).
Co-immunoprecipitation and luciferase assays. Co-immunoprecipitation and
western blotting were performed as described previously27. Briefly, for co-
immunoprecipitation in iOLs and mOLs, 600 mg of cell lysate proteins were
incubated with 3 mg anti-Tcf7l2, anti-Kaiso or anti-Sox10 for immunoprecipitation
assay. For Tcf7l2/b-catenin complex competition assay, in Oli-neu cells, cells were
transfected with 3 mg each pCS2-Myc-Kaiso or pcDNA3-HA-Sox10; in HEK293T
cells, cells were transfected with pcDNA3 Flag-tag Tcf7l2, b-catenin, Myc-tag Kaiso
or pcDNA3-HA-Sox10. For luciferase assays, HEK293T cells were transiently
transfected with pCS2-Myc-tag Kaiso and/or b-catenin9, together with a Topflash
reporter, or transfected with pcDNA3-Flag-Tcf7l2 or Srebf2 with individual
luciferase reporters driven by the enhancers of cholesterol biosynthesis genes. After
western blotting, proteins were detected with appreciate secondary antibodies by
using chemiluminescence with the ECL kit (Pierce) according to the instructions of
the manufacturer. The primers used for cloning of cholesterol biosynthesis gene
promoters are listed in Supplementary Table 1. Western blotting images have been
cropped for presentation. Full-size images for the main figures and for the
Supplementary Figs are presented in Supplementary Figs 11 and 12, respectively.
Quantitative real-time PCR analysis. RNAs were isolated with Trizol (Invitrogen
Inc.) from cells or snap-frozen tissues. Reverse transcription was performed with
the cDNA Reverse Transcription Kit (Bio-Rad) with iQ SYBR Green Supermix
(170-8880). qRT–PCR was carried out using the ABI Prism 7900 Sequence
Detector System (Perkin-Elmer Applied Biosystems) using Gapdh as an internal
control. Each analysis was performed in triplicates and the results were normalized
to Gapdh for each sample. The qRT–PCR primer sequences are listed in
Supplementary Table 1.
RNA-seq and data analysis. We isolated RNAs from the optic nerves of control
mice and Tcf7l2DHMG mutants at P12 and subjected samples to RNA deep
sequencing and data analysis as previously described27. RNA-seq libraries were
prepared using Illumina RNA-seq Preparation Kit (Illumina) and sequenced on a
HiSeq 2000 sequencer. RNA-seq reads were mapped using TopHat with default
settings (http://tophat.cbcb.umd.edu). TopHat output data were then analysed by
Cufflinks to (1) calculate fragments per kilobase of transcript per million mapped
reads values for known transcripts in mouse genome reference and (2) test the
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changes of gene expression between Tcf7l2DHMG and control. Heatmap of gene
differential expression was generated using R language (http://www.r-project.org).
ChIP-sequencing and ChIP–qPCR. ChIP assays were performed as previously
described, with minor modifications27. Briefly, OPCs, iOLs and mOLs (B20
million cells) were fixed for 10min at room temperature with 1%
formaldehyde-containing medium. Nuclei were isolated and sonicated in
sonication buffer (10mM Tris-HCl pH 8.0, 1mM EDTA, 0.5mM EGTA and
protease inhibitor cocktail). Sonicated chromatin (B300mg) was used for
immunoprecipitation by incubation with appropriate antibodies (4 mg) overnight at
4 C. Ten per cent of chromatin used for each ChIP reaction was kept as input
DNA. Prerinsed magnetic protein A/G beads (50 ml) were added to each ChIP
reaction and reactions were incubated for 1 h at 4 C. The beads were then
incubated in 200 ml elution buffer at 65 C for 20min to elute immunoprecipitated
materials. We performed duplicate ChIP-seq assays using chromatin from at least
two different cell cultures. The ChIP-seq libraries were prepared using NEBNext
ChIP-seq Library Prep Master Mix Set for Illumina (NEB catalogue number
E6240L) and then run on the Illumina sequencer HS2000. The antibodies used
were as follows: Kaiso (Abcam, ab12723), TCF7L2 (Santa Cruz, sc-8631) and Sox10
(Abcam, ab155279). The primers used for ChIP–PCR are listed in Supplementary
Table 1.
ChIP-seq peak-calling and data analysis. All sequencing data were mapped to
rat genome assembly rn5 and peak calling was performed as previously described27
using MACS (Model-based Analysis of ChIP-seq) version 1.4.2 (http://
liulab.dfci.harvard.edu/MACS) with default parameters, to get primary binding
regions. To ensure that our data were of high quality and reproducibility, we called
peaks with enrichment Z10-fold over control (Pr10 9) and compared the peak
sets using the ENCODE overlap rules66. These identified primary regions were
further filtered using the following criteria, to define a more stringent
protein–DNA interactome: (1) the P-value cutoff was set to o10 9; (2) an
enrichment of 5-fold and tag number 420, and subtracted with background
regions.
The genome-wide distribution of protein binding regions was determined by
CisGenome2.0 (http://www.biostat.jhsph.edu/Bhji/cisgenome) in reference to
Ensembl RGSC3.4.61 release. This information was also used to group binding
regions by the distance between peak summits and TSS. Venn diagrams were
constructed using 3Venn Applet. De novo motif discovery was performed using
Homer software and novel motifs were compared with JASPAR database
(http://jaspar.genereg.net). For all ChIP-seq data sets, WIG files were generated
with MACS, which were subsequently visualized using Mochiview v1.46. Tcf7l2
ChIP-seq heatmaps were ordered by strength of binding. The heatmaps were
drawn using the Heatmap tools provided by Cistrome (http://cistrome.org/ap).
Gene ontology and enriched motif identification. For ChIP-seq data, binding
peaks in rn5 were annotated with MACS 1.4.2. Functional classification of
annotated binding genes from ChIP-seq and differentially expressed genes in
RNA-seq data was performed using ToppGene (https://toppgene.cchmc.org/).
For RNA-seq data, functional classifications were performed using DAVID
(http://david.abcc.ncifcrf.gov). Enriched motifs of Tcf7l2-binding peaks in mOLs
and iOLs were identified by HOMER (http://homer.salk.edu/homer/ngs/peakMo-
tifs.html). The script ‘findMotifsGenome.pl’ was run for ‘Homer Known Motif
Enrichment Results’ with default parameters.
Cholesterol supplementation in OPC culture and in vivo. Primary mouse OPCs
from P5 to P6 cortices of control and Tcf7l2DHMG pups were prepared by
immunopanning with antibodies Ran-2, GalC and PDGFRa sequentially as
previously described65. Cholesterol (Sigma, C4951) were prepared in ddH2O and
added into the culture medium at 10 mgml 1. Cells in growth medium without
Platelet-derived growth factor-AA were treated with cholesterol or vehicle control
for 4 days and fixed in 4% PFA for 10min, and stained as described.
For the cholesterol-enriched diet feeding experiment, pregnant female mice
were separated into two groups and fed with 2% cholesterol diets (Harlen,
TD.01383) or normal diet, respectively, from the time of gestation when plugs were
detected after initial mating. The control and Tcf7l2DHMG pups were kept
together with their mothers and fed through lactation until harvested at the
indicated time point.
LPC-induced demyelinating injury in the spinal cord. LPC-induced demyeli-
nation was carried out in the ventrolateral spinal white matter of B8-week-old
mice. Anaesthesia was induced and maintained by peritoneal injection of a mixture
of ketamine (90mg kg 1) and xylazine (10mg kg 1). After exposing the spinal
vertebrae at the level of T9–T12, meningeal tissue in the intervertebral space
was cleared and the dura was pierced with a dental needle. One per cent LPC
(L-a-lysophosphatidylcholine; 0.5 ml) via a Hamilton syringe attached to a glass
micropipette was injected into the ventrolateral white matter via a stereotactic
apparatus. Spinal cord tissues carrying the lesions were collected at time points as
follows: 7 dpl, representing peak OPC recruitment, and 14 dpl, representing OL
differentiation and new myelin sheath formation (at least 5 mice per control and
mutant groups were used for each time point analysis).
Electron microscopy. Electron microscopy was performed essentially as
previously described22. Anaesthetized mice were perfused briefly with 0.1M
cacodylate and followed by 2.5% glutaraldehyde/2.5 PFA in 0.1M cacodylate
(pH 7.2). The optic nerves and spinal cord were removed and fixed in fresh fixative
overnight at 4 C. Tissues were rinsed in PBS, postfixed in 1% OsO4 in PBS for 1 h,
dehydrated in a graded ethanol series, infiltrated with propylene oxide and
embedded in Epon. Semi-thin sections were stained with toluidine blue and thin
sections were stained with lead citrate.
Statistical analysis. All analyses were done using Microsoft Excel or GraphPad
Prism 6.00 (San Diego, CA, www.graphpad.com). Quantifications were carried
from at least three independent experimental groups and data were presented as
means±s.e.m. Student’s two-tailed t-tests and one-way analysis of variance
analysis with a Newman–Keuls multiple comparison test were used to compare two
data sets and more than two data sets, respectively. P-valueo0.05 was considered
to be statistically significant.
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